<?xml version='1.0' encoding='utf-8'?>
<document id="30324301"><sentence text="Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016."><entity charOffset="22-33" id="DDI-PubMed.30324301.s1.e0" text="clopidogrel" /></sentence><sentence text="The US Food and Drug Administration (FDA) issued three safety announcements between January 2009 and October 2010 warning against concomitant use of clopidogrel and proton pump inhibitors (PPIs) due to a potential drug-drug interaction that may attenuate clopidogrel's antiplatelet activity"><entity charOffset="149-160" id="DDI-PubMed.30324301.s2.e0" text="clopidogrel" /></sentence><sentence text=" This primary objective of this study was to examine trends in concomitant clopidogrel/PPI use among acute coronary syndrome (ACS) inpatients in the US between 2000 and 2016, in relation to the FDA safety communications"><entity charOffset="75-86" id="DDI-PubMed.30324301.s3.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Adult inpatients with a primary diagnosis of ACS were identified from the Cerner Health FactsÂ® database" /><sentence text=" The standardized (age, sex, race, and census region) prevalence of clopidogrel use with PPIs was calculated yearly and quarterly"><entity charOffset="68-79" id="DDI-PubMed.30324301.s6.e0" text="clopidogrel" /></sentence><sentence text=" Findings were stratified by PPIs' potential to inhibit clopidogrel's activity and by age" /><sentence text="" /><sentence text="A total of 204,533 inpatients were identified" /><sentence text=" In 2008, the prevalence of concomitant clopidogrel and PPI treatment was 34"><entity charOffset="40-51" id="DDI-PubMed.30324301.s10.e0" text="clopidogrel" /></sentence><sentence text="9%, decreasing to 24" /><sentence text="4 and 16" /><sentence text="4% in 2009 and 2010, respectively, with the decline being similar across age groups" /><sentence text=" Treatment with inhibiting PPIs (omeprazole and esomeprazole) and clopidogrel has continued to decrease since 2010, with a prevalence of 0"><entity charOffset="33-43" id="DDI-PubMed.30324301.s14.e0" text="omeprazole" /><entity charOffset="48-60" id="DDI-PubMed.30324301.s14.e1" text="esomeprazole" /><entity charOffset="66-77" id="DDI-PubMed.30324301.s14.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.30324301.s14.e0" e2="DDI-PubMed.30324301.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30324301.s14.e0" e2="DDI-PubMed.30324301.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30324301.s14.e0" e2="DDI-PubMed.30324301.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30324301.s14.e1" e2="DDI-PubMed.30324301.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30324301.s14.e1" e2="DDI-PubMed.30324301.s14.e2" /></sentence><sentence text="8% in 2016" /><sentence text=" A similar reduction was not observed with clopidogrel and non-inhibiting PPIs (pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole)"><entity charOffset="43-54" id="DDI-PubMed.30324301.s16.e0" text="clopidogrel" /><entity charOffset="80-92" id="DDI-PubMed.30324301.s16.e1" text="pantoprazole" /><entity charOffset="94-106" id="DDI-PubMed.30324301.s16.e2" text="lansoprazole" /><entity charOffset="108-119" id="DDI-PubMed.30324301.s16.e3" text="rabeprazole" /><entity charOffset="125-140" id="DDI-PubMed.30324301.s16.e4" text="dexlansoprazole" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e0" e2="DDI-PubMed.30324301.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e0" e2="DDI-PubMed.30324301.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e0" e2="DDI-PubMed.30324301.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e0" e2="DDI-PubMed.30324301.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e0" e2="DDI-PubMed.30324301.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e1" e2="DDI-PubMed.30324301.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e1" e2="DDI-PubMed.30324301.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e1" e2="DDI-PubMed.30324301.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e1" e2="DDI-PubMed.30324301.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e2" e2="DDI-PubMed.30324301.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e2" e2="DDI-PubMed.30324301.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e2" e2="DDI-PubMed.30324301.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e3" e2="DDI-PubMed.30324301.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30324301.s16.e3" e2="DDI-PubMed.30324301.s16.e4" /></sentence><sentence text=" During the FDA warning period, the combined treatment with clopidogrel and H2 receptor antagonists, an alternative to PPIs suggested by the FDA, temporarily increased from 7"><entity charOffset="60-71" id="DDI-PubMed.30324301.s17.e0" text="clopidogrel" /><entity charOffset="76-78" id="DDI-PubMed.30324301.s17.e1" text="H2" /><pair ddi="false" e1="DDI-PubMed.30324301.s17.e0" e2="DDI-PubMed.30324301.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30324301.s17.e0" e2="DDI-PubMed.30324301.s17.e1" /></sentence><sentence text="8% in 2008 to 12" /><sentence text="8 and 14" /><sentence text="5% in 2009 and 2010, respectively" /><sentence text="" /><sentence text="Findings suggest that clinical practice recommendations made by the FDA were followed" /><sentence text=" Further research is needed to determine how changes in drug labels and the availability of new drugs may have influenced the observed trends" /><sentence text="" /></document>